Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22894776 | 0.79 | CXCR4 (0.37) | CYP1A2 | |
| SCHEMBL22894777 | 0.79 | SCN8A (0.32) | SCN8AADORA3ADORA2AADORA2B | |
| SCHEMBL27089125 | 0.74 | — | — | |
| SCHEMBL26693973 | 0.73 | DGAT1 (0.35) | CYP1A2CYP2C19 | |
| SCHEMBL3841245 | 0.72 | DGAT1 (0.33) | CYP2C19HRH3 | |
| SCHEMBL22894779 | 0.72 | CYP1A2 (0.58) | ALDH1A1CYP1A2CYP2C19HRH3 | |
| SCHEMBL2473549 | 0.71 | DGAT1 (0.34) | — | |
| SCHEMBL5870770 | 0.70 | KDM4E (0.38) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL25129886 | 0.69 | MAPT (0.33) | — | |
| SCHEMBL22093251 | 0.69 | DGAT1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| CN-111655261-A | Acyclic CXCR4 inhibitors and uses thereof | X4 制药有限公司 | 2020-09-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009557-A1 | ACYCLIC CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCR3, CXCR1 | SCN8A 3745/4885ALDH1A1 1970/4885CYP1A2 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.